A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Phase 3

Active, not recruiting

• Conditions: Obesity; Diabetes Mellitus, Type 2
• Interventions: Drug: Survodutide; Drug: Placebo

• Registration Number: NCT06066528
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate.

The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity who also have diabetes to lose weight.

Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff.

The doctors check participants' health and take note of any unwanted effects. The study staff also regularly measure participants' body weight. The results are compared between the groups to see whether the treatment works.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-09-27
• Study First Submitted QC: 2023-09-27
• Study First Posted: 2023-10-04
• Study Start: 2023-11-27
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-08
• Last Update Posted: 2025-07-09
• Primary Completion: 2025-12-12
• Study Completion: 2026-04-03

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 756

Inclusion Criteria

1. Male or female, age ≥18 years at the time of signing informed consent, and at least the legal age of consent in countries where it is >18 years.
2. Body mass index (BMI) ≥27 kg/m^2 at screening.
3. Diagnosed with Type 2 diabetes mellitus (T2DM) (defined as Glycosylated haemoglobin A1c (HbA1c) ≥6.5% [≥48 mmol/mol]) at least 180 days prior to screening.
4. HbA1c ≥6.5% (≥48 mmol/mol) and <10% (<86 mmol/mol) as measured by the central laboratory at screening.
5. Currently treated for T2DM with either diet and exercise alone or stable treatment (for at least 3 months prior to screening) per treatment guidelines.
6. History of at least one self-reported unsuccessful dietary effort to lose body weight Further inclusion criteria apply.

Exclusion Criteria

1. Body weight change (self-reported) of >5% within 3 months before screening.
2. Treatment with any medication for the indication obesity within 3 months before screening.
3. Treatment with any medication for indication of T2DM other than stated in the inclusion criteria and glucagon-like peptide-1 receptor (GLP-1R)-based agonists) and dipeptidyl peptidase 4 inhibitor [DPP-4il).
4. Known clinically significant gastric emptying abnormality (e.g., severe diabetic gastroparesis or gastric outlet obstruction).
5. History of either chronic or acute pancreatitis or elevation of serum lipase or amylase >2x upper limit of normal (ULN)) as measured by the central laboratory at screening.
6. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Further exclusion criteria apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Survodutide 3.6 mg	Survodutide	-
Placebo	Placebo	-
Survodutide 6.0 mg	Survodutide	-

Primary Outcome Measures

Name	Time	Method
Percentage change in body weight from baseline to Week 76	Baseline and at Week 76
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76	Baseline and at Week 76

Secondary Outcome Measures

Name	Time	Method
Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76	Baseline and at Week 76
Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76	Baseline and at Week 76
Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76	Baseline and at Week 76
Absolute change from baseline to Week 76 in body weight (kg)	Baseline and at Week 76
Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)	Baseline and at Week 76
Absolute change from baseline to Week 76 in waist circumference (cm)	Baseline and at Week 76
Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)	Baseline and at Week 76
Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of Eating Behaviour patient reported outcome (PRO)	Baseline and at Week 76	"Capacity to Resist" domain score of the Eating Behaviour PRO is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.
Key secondary endpoint: Absolute change from baseline to Week 76 in Eating Behaviour PRO total score	Baseline and at Week 76	Eating Behaviour PRO total score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).
Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)	Baseline and at Week 76
Absolute change from baseline to Week 76 in HbA1c (mmol/mol)	Baseline and at Week 76
Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)	Baseline and at Week 76
Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)	Baseline and at Week 76
Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)	Baseline and at Week 76
Absolute change from baseline to Week 76 in high density lipoprotein (HDL) cholesterol (mg/dL)	Baseline and at Week 76
Absolute change from baseline to Week 76 in low density lipoprotein (LDL) cholesterol (mg/dL)	Baseline and at Week 76
Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) cholesterol (mg/dL)	Baseline and at Week 76
Absolute change from baseline to Week 76 in triglycerides (mg/dL)	Baseline and at Week 76
Absolute change from baseline to Week 76 in free fatty acids (mg/dL)	Baseline and at Week 76
Absolute change from baseline to Week 76 in total cholesterol (mg/dL)	Baseline and at Week 76
Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)	Baseline and at Week 76
Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)	Baseline and at Week 76

Trial Locations

Locations (143)

Pinnacle Research Group, LLC; 🇺🇸 Anniston, Alabama, United States

EmVenio Research-Atlanta-69582; 🇺🇸 Phoenix, Arizona, United States

Encompass Clinical Research, Spring Valley; 🇺🇸 Spring Valley, California, United States

Diablo Clinical Research; 🇺🇸 Walnut Creek, California, United States

Alliance for Multispecialty Research-Coral Gables-68872; 🇺🇸 Coral Gables, Florida, United States

University of Florida; 🇺🇸 Gainesville, Florida, United States

East Coast Institute for Research, LLC-Jacksonville-55146; 🇺🇸 Jacksonville, Florida, United States

New Horizon Research Center-Miami-69732; 🇺🇸 Miami, Florida, United States

West Orange Endocrinology; 🇺🇸 Ocoee, Florida, United States

Emory University; 🇺🇸 Atlanta, Georgia, United States

Scroll for more (133 remaining)